T-20 (enfuvirtide, Fuzeon)

The red rash and nodules that occur at the injection site of as many as 98% of people administering T-20 (enfuvirtide, Fuzeon) is often described as a hypersensitivity reaction, but its cause is not well understood.1 Other symptoms suggestive of hypersensitivity include fever, respiratory distress, and low blood pressure. The reaction may be relieved using antihistamines, topical corticosteroids, or massage.

References

  1. Lalezari JP et al. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N Engl J Med 348: 2175-2185, 2003
Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.